Clinical Effects of Limosilactobacillus Reuteri Probiotics as an Adjunct to the Treatment of Periodontitis

The purpose of this study is to evaluate the clinical efficacy of a probiotic lozenge containing Limosilactobacillus reuteri as an adjunct to the periodontal non-surgical treatment of patients with stage II, grade A, B and C, generalized periodontitis.

Inclusion Criteria:Patients over 18 years old, who intend to voluntarily participate in the study and:Have a definitive diagnosis of stage II, grade A, B or C, generalized periodontitis (2018, World Workshop);Have at least 3 natural teeth maintained per quadrant.Exclusion Criteria:• Patients unable to understand the instructions necessary to participate in the study or unable to give informed consent;Patients who have received any type of periodontal treatment 2 months prior to the start of study participation;Pregnant or breastfeeding patients;Patients with associated systemic pathology, such as diabetes, HIV, asthma, hyperthyroidism, immune system pathologies, lichen erosive or other pathologies treated with corticosteroids or immunosuppressants;Patients undergoing therapy with drugs that may interfere with the response of the gingival tissues: anti-inflammatory drugs, anticonvulsants (phenytoin and sodium valproate), immunosuppressants (cyclosporin-A and tacrolimus) and antihypertensives (nifedipine and verapamil hydrochloride);Patients undergoing anticoagulant therapy;Patients allergic to both lidocaine, articaine and mepivacaine;Patients who require antibiotic prophylaxis for bacterial endocarditis;Patients who have had antibiotic therapy within 2 months of study participation;Patients using chlorhexidine, or other mouthwashes or elixirs;Patients undergoing orthodontic treatment.